TCR gene-engineered cell therapy for solid tumors

Best Pract Res Clin Haematol. 2021 Sep;34(3):101285. doi: 10.1016/j.beha.2021.101285. Epub 2021 Jul 9.

Abstract

The engineering of immune cells to target cancer cells (cellular immunotherapy) has been an exciting area of development in recent years. One type of cellular therapy, T cell receptor (TCR) gene engineered therapy, has shown particular promise in solid tumors. Through use of a heterodimer to recognize intracellular tumor antigens presented through the major histocompatibility complex (MHC), TCR T cells are able to evoke a cytotoxic response as well as a clinical response. In this review, we discuss the potential of TCR-based cellular therapies in solid tumors. While various challenges exist with this therapy, multiple clinical trials are ongoing, in attempt to mitigate these limitations.

Keywords: Cellular therapy; Solid tumors; TCR.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm
  • Cell- and Tissue-Based Therapy
  • Genes, T-Cell Receptor
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms* / genetics
  • Neoplasms* / therapy
  • Receptors, Antigen, T-Cell* / genetics

Substances

  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell